This list is an analysis based on recent market events. It's not an investment recommendation.
About
Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori. Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden.
Depending on the exchange, the stock ticker may vary. For instance, on Grey Market exchange Cinclus Pharma AB stocks are traded under the ticker CPHHF.
When is the next Cinclus Pharma AB earnings date?▼
Cinclus Pharma AB is going to release the next earnings report on November 11, 2026.
What is Cinclus Pharma AB revenue for the last year?▼
Cinclus Pharma AB revenue for the last year amounts to 6.23M USD.
What is Cinclus Pharma AB net income for the last year?▼
CPHHF net income for the last year is -19.94M USD.
How many employees does Cinclus Pharma AB have?▼
As of November 8, 2026, the company has 17 employees.
In which sector is Cinclus Pharma AB located?▼
Cinclus Pharma AB operates in the Other sector.
When did Cinclus Pharma AB complete a stock split?▼
Cinclus Pharma AB has not had any recent stock splits.
Where is Cinclus Pharma AB headquartered?▼
Cinclus Pharma AB is headquartered in Stockholm, Sweden.